

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UNITED GENE HIGH-TECH GROUP LIMITED

聯合基因科技集團有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

CLARIFICATION ANNOUNCEMENT

Reference is made to the circular dated 26 June 2014 (the “**Circular**”) of United Gene High-Tech Group Limited (the “**Company**”) and the announcement dated 10 July 2014 of the Company (the “**Announcement**”). Capitalized terms used herein shall have the same meanings as those defined in the Circular and Announcement unless defined otherwise.

The Board wishes to clarify that due to inadvertent clerical errors, certain information in the Circular were mistakenly stated. The relevant errors and corrections made are as follows:

A figure in the first paragraph of page 42 of the letter from the Board of the Circular under the heading “Major bases and assumptions used in the Financial Projections” was mistyped, the correct wordings should read as follows (with the revised number bold and underlined):

*“Based on the valuation report dated 26 June 2014 prepared by Roma, Registered Professional Surveyors and an independent professional valuer, the appraised market value of the equity interest of the Target Group (as 100% equity interest in the Target Company together with its 51% equity interests in Fosse Bio and Welly Surplus and 100% equity interest of Nation Joy) as at 28 February 2014 amounted to approximately **HK\$2,020,000,000.**”*

Save and except for the said clarification, all the information in the Circular remains unchanged.

By Order of the Board
United Gene High-Tech Group Limited
Lee Nga Yan
Executive Director

Hong Kong, 20 August 2014

As at the date of this announcement, the Board comprises Ms. Jiang Nian (chairman & non-executive Director), Ms. Lee Nga Yan (executive Director), Dr. Guo Yi (executive Director), Ms. Xiao Yan (non-executive Director), Ms. Wu Yanmin (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Dr. Zhang Zhihong (independent non-executive Director) and Mr. Wang Rongliang (independent non-executive Director).